Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity

Authors: Abraham, N. G.; Tsenovoy, P. L.; McClung, J.; Drummond, G. S.

Source: Current Pharmaceutical Design, Volume 14, Number 5, February 2008 , pp. 412-421(10)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

The full text is free.

View now:

PDF 370.5kb

Abstract:

Heme oxygenase-1 (HO-1) is central to the regulation of oxidative injury. The role of increased HO-1 expression and Heme oxygenase (HO) activity in mitigating the detrimental side effect of diabetes is examined. A review of the mechanism(s) of action is included. This may lead to the development of pharmacological and genetic approaches to mitigate the clinical complications associated with the progression of diabetes and obesity.

Keywords: Diabetes; Carbon monoxide; bilirubin; HO-1; Inflamation; TNF; IL-1; adiponectin

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138161208783597371

Affiliations: 1: New York Medical College, Director of Gene Therapy, Room 527, Valhalla NY 10595, USA.

Publication date: 2008-02-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.